TY - JOUR
T1 - Serumuric acidandthe riskof cardiovascular and renal disease
AU - Borghi, Claudio
AU - Rosei, Enrico Agabiti
AU - Bardin, Thomas
AU - Dawson, Jesse
AU - Dominiczak, Anna
AU - Kielstein, Jan T.
AU - Manolis, Athanasios J.
AU - Perez-Ruiz, Fernando
AU - Mancia, Giuseppe
PY - 2015
Y1 - 2015
N2 - Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular diseases. This highlights the need for greater attention to serum uric acid levels when profiling patients, and suggests that the threshold above which uricemia is considered abnormal is 6 mg/dl, in light of the available evidence. Another important question is whether lowering serum uric acid can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients; the available literature shows a trend toward improvement associated with administration of urate-lowering drugs, in particular for the xanthine oxidase inhibitors. The demonstrated efficacy of urate-lowering therapy on outcomes other than gout flares leads to the consideration that treatment may be beneficial even in the absence of overt gout when hyperuricemia accompanies other clinical conditions, such as urate deposition, advanced CKD or cardiovascular risk factors.
AB - Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular diseases. This highlights the need for greater attention to serum uric acid levels when profiling patients, and suggests that the threshold above which uricemia is considered abnormal is 6 mg/dl, in light of the available evidence. Another important question is whether lowering serum uric acid can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients; the available literature shows a trend toward improvement associated with administration of urate-lowering drugs, in particular for the xanthine oxidase inhibitors. The demonstrated efficacy of urate-lowering therapy on outcomes other than gout flares leads to the consideration that treatment may be beneficial even in the absence of overt gout when hyperuricemia accompanies other clinical conditions, such as urate deposition, advanced CKD or cardiovascular risk factors.
KW - Cardiovascular disease
KW - Hyperuricemia
KW - Renal disease
KW - Serum uric acid
UR - http://www.scopus.com/inward/record.url?scp=84942589687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942589687&partnerID=8YFLogxK
U2 - 10.1097/HJH.0000000000000701
DO - 10.1097/HJH.0000000000000701
M3 - Article
C2 - 26136207
AN - SCOPUS:84942589687
SN - 0263-6352
VL - 33
SP - 1729
EP - 1741
JO - Journal of Hypertension
JF - Journal of Hypertension
IS - 9
ER -